Keymed and Lepu Biopharma Jointly Announce Global Exclusive Licence Agreement with AstraZeneca for CMG901

Keymed Biosciences releases 2021 annual results

Keymed has been included as eligible stocks of the Shenzhen-Hong Kong Stock Connect

Keymed Bio joins Hang Seng Family of Indexes